{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:51:56Z","timestamp":1790254316621,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00198-020-05324-0","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:06:04Z","timestamp":1581440764000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study"],"prefix":"10.1007","volume":"31","author":[{"given":"E. M. C.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dinavahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. C.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maddox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"5324_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761\u20131767. https:\/\/doi.org\/10.1016\/S0140-6736(02)08657-9","journal-title":"Lancet"},{"key":"5324_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00776-006-1056-3","volume":"11","author":"T Fukushima","year":"2006","unstructured":"Fukushima T, Sudo A, Uchida A (2006) Bilateral hip fractures. J Orthop Sci 11:435\u2013438. https:\/\/doi.org\/10.1007\/s00776-006-1056-3","journal-title":"J Orthop Sci"},{"key":"5324_CR3","unstructured":"International Osteoporosis Foundation (2013) The Asia-Pacific regional audit: epidemiology, costs and burden of osteoporosis in 2013. Nyon, Switzerland"},{"key":"5324_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3346\/jkms.2016.31.1.89","volume":"31","author":"HM Cho","year":"2016","unstructured":"Cho HM, Lee K, Min W, Choi YS, Lee HS, Mun HJ, Shim HY, Lee DG, Yoo MJ (2016) Survival and functional outcomes after hip fracture among nursing home residents. J Korean Med Sci 31:89\u201397. https:\/\/doi.org\/10.3346\/jkms.2016.31.1.89","journal-title":"J Korean Med Sci"},{"key":"5324_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","journal-title":"Osteoporos Int"},{"key":"5324_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11657-016-0280-5","volume":"11","author":"M Bonafede","year":"2016","unstructured":"Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11:26. https:\/\/doi.org\/10.1007\/s11657-016-0280-5","journal-title":"Arch Osteoporos"},{"key":"5324_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","volume":"28","author":"C Roux","year":"2017","unstructured":"Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28:1765\u20131769. https:\/\/doi.org\/10.1007\/s00198-017-3976-5","journal-title":"Osteoporos Int"},{"key":"5324_CR8","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.afos.2017.08.066","volume":"3","author":"MA Ghazi","year":"2017","unstructured":"Ghazi MA, Sufyan M, Alliuddin A et al (2017) Prevention of subsequent fractures of hip with use of bisphosphonates in Pakistan population. Osteoporos Sarcopenia 3:S36. https:\/\/doi.org\/10.1016\/j.afos.2017.08.066","journal-title":"Osteoporos Sarcopenia"},{"key":"5324_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00223-011-9545-6","volume":"90","author":"H Hagino","year":"2012","unstructured":"Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14\u201321. https:\/\/doi.org\/10.1007\/s00223-011-9545-6","journal-title":"Calcif Tissue Int"},{"key":"5324_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-016-3820-3","volume":"28","author":"F-P Chen","year":"2017","unstructured":"Chen F-P, Shyu Y-C, Fu T-S, Sun CC, Chao AS, Tsai TL, Huang TS (2017) Secular trends in incidence and recurrence rates of hip fracture: a nationwide population-based study. Osteoporos Int 28:811\u2013818. https:\/\/doi.org\/10.1007\/s00198-016-3820-3","journal-title":"Osteoporos Int"},{"key":"5324_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/PL00004148","volume":"7","author":"B Gullberg","year":"1997","unstructured":"Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407\u2013413. https:\/\/doi.org\/10.1007\/PL00004148","journal-title":"Osteoporos Int"},{"key":"5324_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","volume":"4","author":"C-L Cheung","year":"2018","unstructured":"Cheung C-L, Ang SB, Chadha M et al (2018) An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 4:16\u201321. https:\/\/doi.org\/10.1016\/j.afos.2018.03.003","journal-title":"Osteoporos Sarcopenia"},{"key":"5324_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6874-13-7","volume":"13","author":"AW Kung","year":"2013","unstructured":"Kung AW, Fan T, Xu L, Xia WB, Park IH, Kim HS, Chan SP, Lee JK, Koh L, Soong YK, Soontrapa S, Songpatanasilp T, Turajane T, Yates M, Sen S (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 13:7. https:\/\/doi.org\/10.1186\/1472-6874-13-7","journal-title":"BMC Womens Health"},{"key":"5324_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/os.12296","volume":"8","author":"Y Man","year":"2016","unstructured":"Man Y, Pan W, Lu J, Li SY, Zhang P, Guo JZ, Yu SF, Zhang B, Xiao E, Zhang C, Zuo W, Jin HJ, Chen Y, Wu B, Shi XE, Hong D, Liu X, Gao YX, Li J, Yin L, Xue QY (2016) Treatment and management of osteoporotic fractures: a nation-wide survey of 484 senior orthopaedists in China. Orthop Surg 8:432\u2013439. https:\/\/doi.org\/10.1111\/os.12296","journal-title":"Orthop Surg"},{"key":"5324_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00774-016-0758-7","volume":"35","author":"N Suzuki","year":"2017","unstructured":"Suzuki N, Arai K, Kon S, Yamanaka K, Otsuka H, Koizumi M, Hosaka N, Tsuchiya M, Mochizuki T, Kuraishi T, Murayama T, Tashi H, Oike N, Wakasugi M, Takahashi Y, Nakadai M, Endo N (2017) Challenges to prevent secondary fractures in patients with hip fractures in Joetsu Myoko, Japan through the increased use of osteoporosis treatment and collaboration with family doctors. J Bone Miner Metab 35:315\u2013323. https:\/\/doi.org\/10.1007\/s00774-016-0758-7","journal-title":"J Bone Miner Metab"},{"key":"5324_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.afos.2017.05.001","volume":"3","author":"SS Yeap","year":"2017","unstructured":"Yeap SS, Nur Fazirah MFR, Nur Aisyah C, Zahari Sham SY, Samsudin IN, C Thambiah S, Hew FL, Lim BP, Siow YS, Chan SP (2017) Trends in post osteoporotic hip fracture care from 2010 to 2014 in a private hospital in Malaysia. Osteoporos Sarcopenia 3:112\u2013116. https:\/\/doi.org\/10.1016\/j.afos.2017.05.001","journal-title":"Osteoporos Sarcopenia"},{"key":"5324_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.amjmed.2015.01.014","volume":"128","author":"SC Kim","year":"2015","unstructured":"Kim SC, Kim M, Sanf\u00e9lix-Gimeno G et al (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519\u2013526.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2015.01.014","journal-title":"Am J Med"},{"key":"5324_CR18","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s00198-016-3763-8","volume":"27","author":"X Wu","year":"2016","unstructured":"Wu X, Wei D, Sun B, Wu XN (2016) Poor medication adherence to bisphosphonates and high self-perception of aging in elderly female patients with osteoporosis. Osteoporos Int 27:3083\u20133090. https:\/\/doi.org\/10.1007\/s00198-016-3763-8","journal-title":"Osteoporos Int"},{"key":"5324_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00774-014-0621-7","volume":"33","author":"C-Y Hsu","year":"2015","unstructured":"Hsu C-Y, Chiu W-C, Chen J-F, Chou CL, Su YJ, Yu SF, Cheng TT (2015) Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients. J Bone Miner Metab 33:577\u2013583. https:\/\/doi.org\/10.1007\/s00774-014-0621-7","journal-title":"J Bone Miner Metab"},{"key":"5324_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.afos.2016.07.001","volume":"2","author":"EYN Cheung","year":"2016","unstructured":"Cheung EYN, Tan KCB, Cheung C-L, Kung AWC (2016) Osteoporosis in East Asia: current issues in assessment and management. Osteoporos Sarcopenia 2:118\u2013133. https:\/\/doi.org\/10.1016\/j.afos.2016.07.001","journal-title":"Osteoporos Sarcopenia"},{"key":"5324_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11914-012-0114-3","volume":"10","author":"A Mithal","year":"2012","unstructured":"Mithal A, Kaur P (2012) Osteoporosis in Asia: a call to action. Curr Osteoporos Rep 10:245\u2013247. https:\/\/doi.org\/10.1007\/s11914-012-0114-3","journal-title":"Curr Osteoporos Rep"},{"key":"5324_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"5324_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"5324_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","volume":"4","author":"MR McClung","year":"2018","unstructured":"McClung MR (2018) Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia 4:11\u201315. https:\/\/doi.org\/10.1016\/j.afos.2018.03.002","journal-title":"Osteoporos Sarcopenia"},{"key":"5324_CR25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"5324_CR26","unstructured":"Pharmaceuticals and Medical Devices Agency. Prescription drug database: romosozumab (genetically modified) [in Japanese]. http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999449G1"},{"key":"5324_CR27","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"5324_CR28","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, el-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey E, Task Force of the FRAX Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395\u20132411. https:\/\/doi.org\/10.1007\/s00198-011-1713-z","journal-title":"Osteoporos Int"},{"key":"5324_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.aott.2016.06.008","volume":"50","author":"SH Lee","year":"2016","unstructured":"Lee SH, Chen IJ, Li YH, Fan Chiang CY, Chang CH, Hsieh PH (2016) Incidence of second hip fractures and associated mortality in Taiwan: a nationwide population-based study of 95,484 patients during 2006-2010. Acta Orthop Traumatol Turc 50:437\u2013442. https:\/\/doi.org\/10.1016\/j.aott.2016.06.008","journal-title":"Acta Orthop Traumatol Turc"},{"key":"5324_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215. https:\/\/doi.org\/10.1016\/j.bone.2017.07.005","journal-title":"Bone"},{"key":"5324_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Dinavahi R, Crittenden D, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14:59. https:\/\/doi.org\/10.1007\/s11657-019-0608-z","journal-title":"Arch Osteoporos"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-020-05324-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T07:40:28Z","timestamp":1612942828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-020-05324-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5324"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05324-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"20 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CW has received honoraria from Amgen. JM, CT, and WY are employees of Amgen. RD was an employee of Amgen at the time of manuscript development. JG is an employee of UCB Pharma. No other potential conflict of interest relevant to the article was reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Qualified researchers may request data from Amgen clinical studies. Complete details are available at .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}